Swiss pharmaceutical company Roche announced on Monday that it will present late-stage trial results at the ESMO 2026 cancer meeting in Madrid, highlighting new data for its lung cancer drug divarasib, breast cancer pill giredestrant, and experimental drug Tam-Peli, Reuters reported.
The presentation lineup covers multiple oncological targets.
In Plain English: The Clinical Takeaway
- Targeting mutations directly: Divarasib works as a KRAS G12C treatment.
- Oral hormone therapy: Giredestrant is an oral pill for breast cancer that improved outcomes without hurting patients’ quality of life.
- Expanding pipeline reach: Tam-Peli is an experimental drug being evaluated across several hard-to-treat tumours.
Divarasib Lung Cancer Trial Data at ESMO 2026
Roche stated that its late-stage trial data will show divarasib worked better than current KRAS G12C treatments. The data release in Madrid comes as oncology researchers continue to refine targeted inhibitors for thoracic malignancies.
Divarasib’s performance metrics at the European Society for Medical Oncology meeting will offer clinicians a look at the data.
Giredestrant Breast Cancer Outcomes and Quality of Life
In addition to thoracic oncology results, the Swiss drugmaker will unveil findings regarding giredestrant. The data indicate that the breast cancer pill improved outcomes without hurting patients’ quality of life.
Preserving functional status during breast cancer therapy remains a primary objective for clinical trials.
Experimental Tam-Peli Performance in Hard-to-Treat Tumors
The company’s pipeline update also features experimental drug Tam-Peli. Trial disclosures indicate the drug showed strong results in several hard-to-treat tumours.
Detailed profiles for Tam-Peli will be shared during the scientific sessions in Madrid.
| Drug Candidate | Indication | Key Finding Reported |
|---|---|---|
| Divarasib | Lung Cancer | Worked better than current KRAS G12C treatments |
| Giredestrant | Breast Cancer | Improved outcomes without hurting patient quality of life |
| Tam-Peli | Hard-to-Treat Tumors | Showed strong results in several hard-to-treat tumours |
References
- Reuters. (2026, October 19). Roche to unveil lung, breast cancer data at ESMO 2026.
